Specific resurfaced Dengue virus glycoprotein subunit E DIII variants and their uses in preventing and treating Dengue virus infection are disclosed. Provided herein are specific resurfaced Zika virus glycoprotein subunit E DIII variants and their uses in preventing and treating Zika virus infection. Multivalent vaccines comprising such resurfaced EDIII variants are also described, in addition to nanoparticle conjugated resurfaced EDIII variants.

The present invention relates to methods for determining affinity, binding kinetics and/or concentration of an antibody or of an antibody mixture specific for a virus using virus-like particles (VLPs) and/or live viruses or inactivated viruses attached to biosensors. Further, the present invention relates to the VLPs and live or inactivated viruses attached to biosensors and methods for producing them.

Chimeric proteins that comprise one or more amino acid sequences of an insect-specific flavivirus and one or more other immunogenic proteins are provided. The chimeric proteins are suitably capable of forming virus particles. The chimeric protein and/or virus particle may be suitable for delivery to a subject to elicit an immune response to a pathogen and/or for diagnosis or detection of a pathogen. Also provided are nucleic acids and vectors encoding the chimeric proteins, and isolated chimeric insect-specific flaviviruses comprising the chimeric proteins and/or nucleic acids.

The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

Provided is a flavivirus cross neutralizing antibody which has an excellent ability to control infection with suppressed ADE. This is a flavivirus cross neutralizing antibody that specifically binds to domains of E protein of flavivirus and thereby has an ability to control infection with at least two viruses included in the flavivirus. The domains of E protein include a plurality of domains including domain III. The flavivirus includes, for example, Zika virus, dengue virus types 1-4, and Japanese encephalitis virus.

Disclosed herein are methods of delivering an agent to a subject. Further disclosed herein are methods of treating a disease or disorder in a subject. The methods may include administering to the subject a chondroitinase polypeptide or a polynucleotide encoding a chondroitinase polypeptide in an amount sufficient to degrade glycosaminoglycans, and administering to the subject the agent. The methods may further include administering a hyaluronidase polypeptide or a polynucleotide encoding a hyaluronidase.

The present disclosure is directed to antibodies binding to and neutralizing Zika vims and methods for use thereof.

The present disclosure is directed to antibodies binding to and neutralizing dengue virus and methods for use thereof.

Antibodies and antigen-binding fragments thereof specific to the YFV E protein and with neutralizing potency against YFV are provided. These antibodies and antigen-binding fragments are useful in treating YFV.

The present invention provides isolated monoclonal antibodies, or antigen-binding portions thereof, that bind to ZIKV glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies, or antigen-binding portions thereof, according to the present invention are useful for inhibiting or neutralizing ZIKV activity, thus providing a means of treating or preventing ZIKV infection in humans. The antibodies, or antigen-binding portions thereof, according to the present invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.